Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cytochrome P450, putative | 0.0024 | 1 | 0.5 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0024 | 1 | 1 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0024 | 1 | 0.5 |
Brugia malayi | Cytochrome P450 family protein | 0.0024 | 1 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0024 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0024 | 1 | 0.5 |
Trypanosoma brucei | cytochrome P450, putative | 0.0024 | 1 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0024 | 1 | 1 |
Leishmania major | cytochrome p450-like protein | 0.0024 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC25 (functional) | = 0.128 uM | Compound was tested for its effect on coronary vasodilator in isolated rat hearts. | ChEMBL. | 2066997 |
EC25 (functional) | = 0.284 uM | Compound was tested for its effect on coronary vasodilator in isolated rat hearts. | ChEMBL. | 2066997 |
EC25 (functional) | = 0.29 uM | Cardiovascular activity in isolated rat heart, concentration producing 25% increase in CF (cardiac flow). | ChEMBL. | 2066997 |
EC25 (functional) | = 0.47 uM | Cardiovascular activity in isolated rat heart, concentration producing 25% increase in LV + dP/dtmax. | ChEMBL. | 2066997 |
EC25 (functional) | = 0.535 uM | Compound was tested for its effect on ventricular contractility in isolated rat hearts. | ChEMBL. | 2066997 |
EC25 (functional) | = 0.701 uM | Compound was tested for its effect on ventricular cantractility in isolated rat hearts. | ChEMBL. | 2066997 |
EC25 (functional) | = 0.888 uM | Compound was tested for its effect on ventricular cantractility in isolated rat hearts. | ChEMBL. | 2066997 |
EC25 (functional) | = 1.622 uM | Compound was tested for its effect on coronary vasodilator in isolated rat hearts. | ChEMBL. | 2066997 |
IC50 (binding) | = 271 nM | Affinity to bind dihydropyridine receptor (DHP receptor) by inhibiting the radioligand [3H]-nitrendipine | ChEMBL. | 2066997 |
IC50 (binding) | = 0.152 uM | Affinity to bind dihydropyridine receptor (DHP receptor) by inhibiting the radioligand [3H]-nitrendipine | ChEMBL. | 2066997 |
IC50 (binding) | > 1000 uM | Affinity to bind dihydropyridine receptor (DHP receptor) by inhibiting the radioligand [3H]-nitrendipine | ChEMBL. | 2066997 |
Vasoconstriction effect (functional) | = 0 | Vasoconstrictor effect of the compound at a concentration of 10e-5 M in presence of partially depolarized isolated rings from rabbits. | ChEMBL. | 2066997 |
Vasoconstriction effect (functional) | = 0 | Vasoconstrictor effect of the compound at a concentration of 10e-4 M in presence of partially depolarized isolated rings from rabbits. | ChEMBL. | 2066997 |
Vasoconstriction effect (functional) | = 0 | Vasoconstrictor effect of the compound at a concentration of 10e-9 M in presence of nondepolarized isolated rings from rabbits. | ChEMBL. | 2066997 |
Vasoconstriction effect (functional) | = 0 | Vasoconstrictor effect of the compound at a concentration of 10e-8 M in presence of nondepolarized isolated rings from rabbits. | ChEMBL. | 2066997 |
Vasoconstriction effect (functional) | = 0 | Vasoconstrictor effect of the compound at a concentration of 10e-7 M in presence of nondepolarized isolated rings from rabbits. | ChEMBL. | 2066997 |
Vasoconstriction effect (functional) | = 0 | Vasoconstrictor effect of the compound at a concentration of 10e-5 M in presence of nondepolarized isolated rings from rabbits. | ChEMBL. | 2066997 |
Vasoconstriction effect (functional) | = 0 | Vasoconstrictor effect of the compound at a concentration of 10e-4 M in presence of nondepolarized isolated rings from rabbits. | ChEMBL. | 2066997 |
Vasoconstriction effect (functional) | = 2.4 | Vasoconstrictor effect of the compound at a concentration of 10e-6 M in presence of partially depolarized isolated rings from rabbits. | ChEMBL. | 2066997 |
Vasoconstriction effect (functional) | = 3.3 | Vasoconstrictor effect of the compound at a concentration of 10e-9 M in presence of partially depolarized isolated rings from rabbits. | ChEMBL. | 2066997 |
Vasoconstriction effect (functional) | = 4.5 | Vasoconstrictor effect of the compound at a concentration of 10e-8 M in presence of partially depolarized isolated rings from rabbits. | ChEMBL. | 2066997 |
Vasoconstriction effect (functional) | = 5 | Vasoconstrictor effect of the compound at a concentration of 10e-7 M in presence of partially depolarized isolated rings from rabbits. | ChEMBL. | 2066997 |
Vasorelaxant effect (functional) | = -9.1 | Vasorelaxant effect of the compound at a concentration of 10e-7 M on rabbit aortic rings previously contracted with 50 mM KCl. | ChEMBL. | 2066997 |
Vasorelaxant effect (functional) | = -8.6 | Vasorelaxant effect of the compound at a concentration of 10e-8 M on rabbit aortic rings previously contracted with 50 mM KCl. | ChEMBL. | 2066997 |
Vasorelaxant effect (functional) | = -4.8 | Vasorelaxant effect of the compound at a concentration of 10e-9 M on rabbit aortic rings previously contracted with 50 mM KCl. | ChEMBL. | 2066997 |
Vasorelaxant effect (functional) | = -2.3 | Vasorelaxant effect of the compound at a concentration of 10e-6 M on rabbit aortic rings previously contracted with 1.0 uM Norepinephrine. | ChEMBL. | 2066997 |
Vasorelaxant effect (functional) | = -1.8 | Vasorelaxant effect of the compound at a concentration of 10e-7 M on rabbit aortic rings previously contracted with 1.0 uM Norepinephrine. | ChEMBL. | 2066997 |
Vasorelaxant effect (functional) | = -1.4 | Vasorelaxant effect of the compound at a concentration of 10e-8 M on rabbit aortic rings previously contracted with 1.0 uM Norepinephrine. | ChEMBL. | 2066997 |
Vasorelaxant effect (functional) | = -0.9 | Vasorelaxant effect of the compound at a concentration of 10e-9 M on rabbit aortic rings previously contracted with 1.0 uM Norepinephrine. | ChEMBL. | 2066997 |
Vasorelaxant effect (functional) | = 0.7 | Vasorelaxant effect of the compound at a concentration of 10e-5 M on rabbit aortic rings previously contracted with 1.0 uM Norepinephrine. | ChEMBL. | 2066997 |
Vasorelaxant effect (functional) | = 4.2 | Vasorelaxant effect of the compound at a concentration of 10e-4 M on rabbit aortic rings previously contracted with 1.0 uM Norepinephrine. | ChEMBL. | 2066997 |
Vasorelaxant effect (functional) | = 6.2 | Vasorelaxant effect of the compound at a concentration of 10e-6 M on rabbit aortic rings previously contracted with 50 mM KCl. | ChEMBL. | 2066997 |
Vasorelaxant effect (functional) | = 53.8 | Vasorelaxant effect of the compound at a concentration of 10e-5 M on rabbit aortic rings previously contracted with 50 mM KCl. | ChEMBL. | 2066997 |
Vasorelaxant effect (functional) | = 88.9 | Vasorelaxant effect of the compound at a concentration of 10e-4 M on rabbit aortic rings previously contracted with 50 mM KCl. | ChEMBL. | 2066997 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.